Peptide and non-peptide bradykinin receptor antagonists: Role in allergic airway disease

Kinins are proinflammatory peptides that mediate a variety of pathophysiological responses. These actions occur through stimulation of two pharmacologically distinct receptor subtypes B1 and B2. In both human and animal airways, the majority of kinin-induced effects including bronchoconstriction, in...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 2006-03, Vol.533 (1-3), p.215-221
Main Authors: Abraham, William M., Scuri, Mario, Farmer, Stephen G.
Format: Article
Language:English
Subjects:
Airway inflammation
Animal model
Animals
Anti-Inflammatory Agents, Non-Steroidal - pharmacology
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Asthma
Asthma - drug therapy
Asthma - metabolism
Bradykinin - analogs & derivatives
Bradykinin - metabolism
Bradykinin - pharmacology
Bradykinin - therapeutic use
Bradykinin B2 Receptor Antagonists
Disease Models, Animal
Humans
Kinin
Quinolines - pharmacology
Quinolines - therapeutic use
Receptor, Bradykinin B2 - metabolism
Respiratory System - drug effects
Respiratory System - metabolism
Therapy
Tissue Kallikreins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Kinins are proinflammatory peptides that mediate a variety of pathophysiological responses. These actions occur through stimulation of two pharmacologically distinct receptor subtypes B1 and B2. In both human and animal airways, the majority of kinin-induced effects including bronchoconstriction, increases in vascular permeability and mucus secretion and cholinergic and sensory nerve stimulation appear to be bradykinin B2-receptor mediated. Peptidic and non-peptidic receptor antagonists have been developed as potential therapeutic agents. These antagonists are effective in blocking kinin-induced effects in a variety of animal models and in some instances, have been used effectively in animal models of allergic airway disease to alleviate allergen-induced pathophysiological airway responses. This review summarizes relevant studies supporting the evidence that bradykinin B2 receptor antagonism and/or upstream inhibition of tissue kallikrein will be beneficial in the treatment of inflammatory airway diseases.
ISSN:0014-2999
1879-0712
DOI:10.1016/j.ejphar.2005.12.071